Graham Dixon
Chief Tech/Sci/R&D Officer at MITHRA PHARMACEUTICALS S.A.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Laura Ila von Schantz | M | 42 | 10 years | |
Anders Olof Adolf Ekblom | M | 70 | 7 years | |
Wolfgang Albrecht | M | - |
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | 7 years |
Jeffrey Pott | M | - | 29 years | |
Marcus Wallenberg | M | 68 | 25 years | |
Valérie Leroy | F | - | 8 years | |
Peter Ellmark | M | 51 | 6 years | |
Christophe Maréchal | M | - | 7 years | |
Jean-Michel Foidart | M | 75 | 25 years | |
Denise Goode | F | 66 | 2 years | |
Marie Svensson | F | 60 | 4 years | |
Hans-Peter Albert Ostler | M | 53 | 3 years | |
Eva Ulrika Sjökvist Saers | M | 62 | 3 years | |
Christian Homsy | M | 65 | 1 years | |
Roel Q. J. Schaapveld | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 16 years |
Søren Bregenholt | M | 53 | 3 years | |
Inge Beernaert | M | - | 1 years | |
Fanny Rozenberg | F | - | - | |
Stijn Vlaminck | M | - | 3 years | |
Sumeet Ambarkhane | M | 56 | 2 years | |
Laurence Schyns | F | - | 3 years | |
Cedric Darcis | M | - | - | |
Iskra Reic | F | - | 23 years | |
Benjamin Brands | M | - | 15 years | |
André Ostachkov | M | - |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | 5 years |
Wilko de Vette | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
Lotfi Yelles Chaouche | M | - |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | 5 years |
Bart Wuurman | M | - |
Apaxen SA
Apaxen SA BiotechnologyHealth Technology Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020. | 4 years |
Jean-Manuel Fontaine | M | - | 11 years | |
Brian S. Bronk | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
Samuel Gerssen | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
Lucas de Breed | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | - |
Elias Papatheodorou | M | 55 |
HepaRegeniX GmbH
HepaRegeniX GmbH Miscellaneous Commercial ServicesCommercial Services HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany. | 2 years |
Audrey Legentil-Duméry | F | - | 9 years | |
Jacques Galloy | M | 53 | 1 years | |
Staffan Encrantz | M | 73 | 2 years | |
Johannes G. C. P. Schikan | M | 66 |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 9 years |
Edwin Cuppen | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 18 years |
Margareta Elisabeth Björk | M | 63 | 22 years | |
Ruud Dobber | M | - | 27 years | |
Eugene Berezikov | M | - |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 18 years |
Andrea van Elsas | M | 58 |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | 3 years |
Valérie Gordenne | F | 51 | 3 years | |
Eva Sjökvist Saers | M | 62 | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Julie Brown | F | 62 |
Zeneca Garden Care
Zeneca Garden Care Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The private company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million. | 21 years |
François Fornieri | M | - | 23 years | |
Patrick J. Langlois | M | 78 | 5 years | |
David Brennan | M | 70 | 13 years | |
Peter James Arthur Benson | M | 69 | 10 years | |
Patricia van Dijck | M | 59 | - | |
Ajit Shetty | M | 77 | - | |
Raj Bhikhu Parekh | M | 63 | 19 years | |
Lennart Erik Jonas Sjögren | M | 58 | 6 years | |
Håkan Söderberg | M | - | 5 years | |
Howard Mitchell Rowe | M | 55 | 12 years | |
An Cloet | F | 53 | 2 years | |
Anna Ulrika Danielsson | F | 52 | 5 years | |
Gavin Hill | M | 56 | 8 years | |
Piet Wigerinck | M | 58 | 13 years | |
Jean Bizzari | M | 69 | - | |
Malin Carlsson | M | 56 | 3 years | |
Liesbeth Weynants | F | 53 | 2 years | |
Per Norlén | M | 54 | 11 years | |
Olivier de Beaumont | M | - | 5 years | |
David Smith | M | 58 | 10 years | |
Erik van den Eynden | M | 56 | 2 years | |
Veronica Wallin | F | 38 | - | |
Michael Zinda | M | 53 | 16 years | |
Julie Silber | F | 56 | - | |
Jean-Pierre Kinet | M | 70 | 4 years | |
Rudi Pauwels | M | 65 | 11 years | |
Marc. A. A. A. L Coucke | M | 59 | - | |
Vicki Sato | M | 75 | 3 years | |
Ferdinand Verdonck | M | 81 | 8 years | |
Werner Cautreels | M | 71 | - | |
Peter Bonfield | M | 79 | 12 years | |
Angus Russell | M | 68 |
Zeneca Garden Care
Zeneca Garden Care Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The private company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million. | 19 years |
Christian Moretti | M | 78 | 2 years | |
Karl Arne Krister Borrebaeck | M | 76 | 20 years | |
Kirsten Drejer | M | 68 | 2 years | |
Tova Landström | M | - | - | |
Harrold van Barlingen | M | 58 | 13 years | |
Cecilia Hofvander | F | - | 4 years | |
Kenth Ingemar Petersson | M | 68 | 20 years | |
Debra White | F | 62 | 13 years | |
Percy N. Barnevik | M | 83 | 5 years | |
Donna Dea | F | - | 18 years | |
Barry Greene | M | 60 | 2 years | |
Joseph Jimenez | M | 64 | 5 years | |
Tom Morris | M | 61 | 18 years | |
Lilian Birgitta Wikström | M | 63 | 5 years | |
Michael Pragnell | M | 77 | 3 years | |
Moira Daniels | F | 62 | 12 years | |
Maria Koehler | M | 67 | 7 years | |
Jan Lundberg | M | 70 | 11 years | |
Peter Kiener | M | 72 | 8 years | |
Nils Anders Haegerstrand | M | 63 | 1 years | |
Roger Adsett | M | 55 | 11 years | |
Hongming Chen | M | 53 | 3 years | |
Elaine Sullivan | M | 63 | 15 years |
Statistics
Country | Connections | % of total |
---|---|---|
Belgium | 32 | 32.00% |
United Kingdom | 29 | 29.00% |
Sweden | 23 | 23.00% |
Netherlands | 9 | 9.00% |
France | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Graham Dixon
- Personal Network